Group 1 - The core point of the article highlights that there are no new IPO applications this week, while the third IPO of the year has been accepted on the Sci-Tech Innovation Board [1][2][4] - Ningbo Jianxin Superconducting Technology Co., Ltd. (referred to as "Jianxin Superconducting") has had its IPO application accepted, aiming to raise 865 million yuan [2][3] - Jianxin Superconducting specializes in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, with its products accounting for approximately 50% of the cost of MRI equipment [3][4] Group 2 - Jianxin Superconducting is one of the earliest manufacturers in China to produce high-field superconducting magnets at scale, breaking the long-standing monopoly of foreign companies [3] - The company has established partnerships with well-known MRI equipment manufacturers, including Fujifilm, GE Healthcare, and others [3] - In terms of market share, Jianxin Superconducting ranks fifth globally and second domestically in the superconducting magnet sector, with a 4.2% global market share [3] Group 3 - The company plans to use the funds raised from the IPO for projects including the annual production of 600 sets of helium-free superconducting magnets and technological upgrades for high-field medical superconducting magnets [4] - The article notes that Jianxin Superconducting's acceptance for IPO reflects the ongoing effects of the "Eight Articles of the Sci-Tech Innovation Board" policy [4] - In total, 13 IPOs have been accepted this year across the Shanghai, Shenzhen, and Beijing exchanges, with three on the Shanghai exchange, all from the Sci-Tech Innovation Board [4]

Group 1 - The core viewpoint of the news is the acceptance of the IPO application of Ningbo Jianxin Superconducting Technology Co., Ltd. on the Sci-Tech Innovation Board, marking it as the third company to be accepted for IPO this year [1][2]. - Jianxin Superconducting focuses on the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, with its main products including superconducting magnets, permanent magnets, and gradient coils, which account for approximately 50% of the cost of MRI equipment [2][3]. - The company has established partnerships with well-known MRI equipment manufacturers such as Fujifilm, GE Healthcare, and others, positioning itself as a leading independent supplier of superconducting magnets globally [2][3]. Group 2 - Jianxin Superconducting's projected revenues for 2022 to 2024 are 359 million yuan, 451 million yuan, and 425 million yuan, respectively, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan [3]. - The IPO aims to raise 865 million yuan for projects including the annual production of 600 sets of helium-free superconducting magnets and the technological transformation of high-field medical superconducting magnets [3]. - The acceptance of Jianxin Superconducting's IPO application highlights the ongoing effects of the "Eight Policies of the Sci-Tech Innovation Board," with a total of 13 IPOs accepted this year across various exchanges [3][8].

Summary of Key Points Core Viewpoint - The week of May 6 to May 11 saw the acceptance of 2 new IPO applications in the Shanghai and Shenzhen stock exchanges, while 2 companies withdrew their IPO applications, and 1 company received registration approval. Group 1: New IPO Applications - Two new IPO applications were accepted on May 9, including Ningbo Jianxin Superconducting Technology Co., Ltd. for the Shanghai Stock Exchange's Sci-Tech Innovation Board and Hangzhou Lianchuan Biotechnology Co., Ltd. for the Beijing Stock Exchange [1][3] - Jianxin Superconducting is the third company accepted for the Sci-Tech Innovation Board this year, focusing on the R&D, production, and sales of core components for MRI equipment [3] - Jianxin Superconducting reported revenues of 359 million yuan, 451 million yuan, and 425 million yuan for 2022 to 2024, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan respectively [3][4] - Lianchuan Biotechnology previously attempted to list on the Sci-Tech Innovation Board but withdrew its application and is now seeking to raise 300 million yuan, half of its previous target [4] Group 2: Terminated IPO Applications - Two companies withdrew their IPO applications: Wuxi Yelong Precision Machinery Co., Ltd. and Shenzhen Haobo Window Control Technology Co., Ltd. [1][6] - Wuxi Yelong, which specializes in turbocharger components, withdrew its application over a year after approval due to the impact of electric vehicles on its business [6][7] - Haobo Window Control reported a revenue decline of 2.46% in the first half of 2024 and expects a full-year revenue drop of 10.76% to 12.68% [8]